Taysha Gene Therapies Inc (NASDAQ: TSHA) established initial surge of 6.49% at $5.09, as the Stock market unbolted on Thursday, before settling in for the price of $4.78 at the close. Taking a more long-term approach, TSHA posted a 52-week range of $1.05-$6.02.
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -63.99%. Meanwhile, its Annual Earning per share during the time was -63.99%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -0.77%. This publicly-traded company’s shares outstanding now amounts to $273.92 million, simultaneously with a float of $218.35 million. The organization now has a market capitalization sitting at $1.39 billion.
Taysha Gene Therapies Inc (TSHA) Ownership Facts and Figures
Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the Taysha Gene Therapies Inc industry. Taysha Gene Therapies Inc’s current insider ownership accounts for 20.29%, in contrast to 90.45% institutional ownership. According to the most recent insider trade that took place on Jan 12 ’26, this organization’s President and Head of R&D sold 200,000 shares at the rate of 4.71, making the entire transaction reach 942,000 in total value, affecting insider ownership by 1,006,439.
Taysha Gene Therapies Inc (TSHA) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.1 per share during the current fiscal year.
Taysha Gene Therapies Inc’s EPS decrease for this current 12-month fiscal period is -0.77% and is forecasted to reach -0.45 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -10.28% through the next 5 years, which can be compared against the -63.99% growth it accomplished over the previous five years trading on the market.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Trading Performance Indicators
Let’s observe the current performance indicators for Taysha Gene Therapies Inc (TSHA). It’s Quick Ratio in the last reported quarter now stands at 10.47. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 220.96.
In the same vein, TSHA’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.35, a figure that is expected to reach -0.10 in the next quarter, and analysts are predicting that it will be -0.45 at the market close of one year from today.
